Gerta Hoxhaj
Pins down how the diabetes drug metformin reaches mTOR in the liver, through AMPK and the TSC complex
BSc, Boğaziçi University, Istanbul · PhD, MRC Protein Phosphorylation Unit, Univ. of Dundee (2013) · postdoc, Brendan Manning lab, Harvard T.H. Chan School (2013–2019) · now Associate Professor, UT Southwestern (since 2019)
Children's Medical Center Research Institute (CRI), UT Southwestern Medical Center ↗
As Manning-lab postdoc, part of team (HOW2017) showing at low doses metformin suppresses hepatic mTORC1 specifically via AMPK and TSC complex. Co-authored with Manning a widely cited PI3K-AKT-mTOR review (HOX2019).
PhD at MRC Dundee characterizing E3 ligase ZNRF2.
Own lab since 2019, CPRIT Scholar, Pew Scholar, V Foundation Scholar, ACS Research Scholar; TAMEST Mary Beth Maddox Award 2025.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2017 | M | Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex HOW2017 Metformin suppresses hepatic mTORC1 via AMPK and TSC at low doses. |
| 2019 | R | The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism HOX2019 Co-authors major review mapping PI3K-AKT-mTOR network. |
On the programme
Meetings in the Atlas calendar where Gerta Hoxhaj is listed among the speakers or organisers.
- past Prague Metabolism and Signaling Symposium 2026 ↗ 24–27 Jun 2026 · Prague, Czech Republic · Tier 1